Questcor Pharmaceuticals Inc. (QCOR): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Questcor Pharmaceuticals ( QCOR) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.5%. By the end of trading, Questcor Pharmaceuticals fell $1.45 (-2.2%) to $63.71 on average volume. Throughout the day, 1,624,836 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 1,987,500 shares. The stock ranged in price between $61.86-$65.26 after having opened the day at $65.21 as compared to the previous trading day's close of $65.16. Other companies within the Drugs industry that declined today were: KaloBios Pharmaceuticals ( KBIO), down 10.0%, Oramed Pharmaceuticals ( ORMP), down 9.5%, Star Scientific ( STSI), down 8.0% and Repros Therapeutics ( RPRX), down 7.8%.

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications. It primarily offers H.P. Questcor Pharmaceuticals has a market cap of $4.1 billion and is part of the health care sector. The company has a P/E ratio of 15.4, below the S&P 500 P/E ratio of 17.7. Shares are up 19.7% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Ohr Pharmaceutical ( OHRP), up 11.6%, Cumberland Pharmaceuticals ( CPIX), up 11.1%, Cambrex Corporation ( CBM), up 10.4% and Receptos ( RCPT), up 8.3% , were all gainers within the drugs industry with Gilead ( GILD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Cramer: Reviewing S&P's Hit-and-Miss Parade

Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015

Greenberg on the Stock Market: Why Investigations No Longer Matter

Retrophin CEO Under Fire for Twitter Faux Pas

Questcor Pharmaceuticals (QCOR) Hits New Lifetime High Today